DUBLIN--(BUSINESS WIRE)--The "Global Virus Filtration Market - Segmented by Product (Kits & Reagents, Filtration Systems, Services, and other Products), Application, End-User, and Geography - Growth, Trends and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.
The Global Virus Filtration market is projected to grow at a CAGR of approximately 12% during the forecast period (2018-2023).
The market is experiencing considerable growth due to factors like increasing R&D spending, growth in biopharmaceutical industry, and increasing government support for the pharmaceutical and biotechnology industry.
Growth in Biopharmaceutical Industry
According to estimates, the global biopharmaceuticals market is estimated to reach USD 341.16 billion in 2023. Biotechnology derived medicinal products are presently the best characterized biologicals with considerable production and clinical experience, and have revolutionized the treatment of some of the most difficult-to-treat diseases, prolonging and improving the quality of life and patient care.
Opportunities in biopharmaceuticals have been constantly increasing over the past decade. The efficacy and the safety of the drugs are some of the key product features that drive the market's growth. There have been biopharmaceutical products that are improving the quality of life and reducing the death rates in patients with HIV/AIDS, cancer, cystic fibrosis, and rheumatoid arthritis.
Biopharmaceuticals have reduced the number of deaths caused due to cancer and HIV/AIDS in the last decade. The efficacy of the drugs and their safety has increased the acceptance for biopharmaceuticals. This growth in biopharmaceutical industry has spurred the growth of virus filtration market. Virus filtration technologies are both directly and indirectly exploited in biopharmaceutical industry.
Key Highlights
- Stringent Regulations for Validation of Filtration Products
- North America has the Largest Share in the Global Virus Filtration Market
Major Market Developments
- Asahi Kasei Medical announced the construction of a new plant for the production of cellulose hollow-fiber membranes for PlanovaTMvirus removal filters in Nobeoka, Miyazaki, Japan, increasing annual production capacity by 40,000 m2/year. The construction is schedule to complete in May 2019.
Companies Profiled
- Asahi Kasei Medical Co. Ltd.
- Charles River Laboratories International Inc.
- General Electric Company
- Lonza Group Ltd.
- Merck KGaA
- Pall Corporation
- Sartorius AG
- Sigma-Aldrich Corporation
- Thermo Fischer Scientific Inc.
- Wuxi Pharmatech (Cayman) Inc.
Topics Covered
1. Introduction
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
7. Market Segmentation
8. Competetive Landscape & Company Profiles
9. Future of the Market
For more information about this report visit https://www.researchandmarkets.com/research/prlvdj/global_virus?w=4
